Dare Bioscience (DARE) announced it received a payment of $2.5M as the latest installment under a grant agreement to advance the development of Dare’s investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug, IND, application with the FDA, approval of which will be required to commence testing in humans. Under the terms of the grant agreement, Dare may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. To date, Dare has received payments totaling approximately $31.8 million. Additional payments are conditioned on the program meeting specified development and reporting milestones.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DARE:
- Dare Bioscience files to sell 2.75M shares of common stock for holders
- Daré Bioscience: Advancing Women’s Health Innovations
- Dare Bioscience reports Q3 EPS (55c), consensus (71c)
- Dare Bioscience announces grant to develop non-hormonal contraceptive candidate
- DARE Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
